Abstract Objective To study the role of interleukin-33 (IL-33) in the development and progression of bronchopulmonary dysplasia (BPD) in preterm infants. Methods A prospective cohort study was performed on 128 preterm infants with a gestational age of ≤ 32 weeks and/or a birth weight of ≤ 1 500 g. They were classified to a non-BPD group with 50 infants, a mild BPD group with 32 infants, a moderate BPD group with 30 infants, and a severe BPD group with 16 infants. Related data were collected, including antepartum factors of mothers (antepartum hormone and chorioamnionitis), intrapartum factors of preterm infants (sex, gestational age, birth weight, mode of birth, and birth asphyxia), treatment after birth (pulmonary surfactant, duration of invasive ventilation, duration of noninvasive ventilation, duration of parenteral nutrition, and length of hospital stay). The high-risk factors for BPD were analyzed. ELISA was used to measure the serum level of IL-33 in preterm infants on days 1, 14, and 28 after birth. The serum level of IL-33 was compared between groups at different time points after birth. The preterm infants with moderate or severe BPD were treated with conventional corticosteroid therapy (DART regimen), and the serum level of IL-33 was measured before and after treatment. Results There were significant differences between the preterm infants with BPD and those without BPD in the incidence of maternal chorioamnionitis, gestational age, birth weight, the incidence of birth asphyxia, duration of invasive ventilation, duration of noninvasive ventilation, duration of parenteral nutrition, and total length of hospital stay (P < 0.05). There were significant differences in the above indices among the preterm infants with different severities of BPD (P < 0.05). On days 1, 14, and 28 after birth, the infants with BPD had a significantly higher serum level of IL-33 than those without BPD, and the serum level of IL-33 tended to increase with the severity of BPD and over the time after birth (P < 0.05). The preterm infants with moderate or severe BPD had a significant reduction in the serum level of IL-33 after the treatment with DART regimen (P < 0.05). Conclusions Serum IL-33 is closely associated with the development and severity of BPD. Anti-inflammatory therapy with DART regimen can decrease the serum level of IL-33.
Cakir U, Tayman C, Yucel C. A novel diagnostic marker for the severity of bronchopulmonary dysplasia in very low birth weight infants:interleukin-33[J]. Pediatr Allergy Immunol Pulmonol, 2019, 32(1):12-17.
[3]
Lal CV, Ambalavanan N. Cellular and humoral biomarkers of bronchopulmonary dysplasia[J]. Early Hum Dev, 2017, 105:35-39.
[4]
Tang X. Interleukin-33(IL-33) increases hyperoxia-induced bronchopulmonary dysplasia in newborn mice by regulation of inflammatory mediators[J]. Med Sci Monit, 2018, 24:6717-6728.
[5]
de Kleer IM, Kool M, de Bruijn MJ, et al. Perinatal activation of the interleukin-33 pathway promotes type 2 immunity in the developing lung[J]. Immunity, 2016, 45(6):1285-1298.
Davidson LM, Berkelhamer SK. Bronchopulmonary dysplasia:chronic lung disease of infancy and long-term pulmonary outcomes[J]. J Clin Med, 2017, 6(1):4.
[9]
Kersbergen KJ, de Vries LS, van Kooij BJ, et al. Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants[J]. J Pediatr, 2013, 163(3):666-671.e1.
[10]
Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease[J]. Nat Rev Immunol, 2016, 16(11):676-689.
[11]
Nabe T, Wakamori H, Yano C, et al. Production of interleukin (IL)-33 in the lungs during multiple antigen challenge-induced airway inflammation in mice, and its modulation by a glucocorticoid[J]. Eur J Pharmacol, 2015, 757:34-41.
[12]
Christianson CA, Goplen NP, Zafar I, et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33[J]. J Allergy Clin Immunol, 2015, 136(1):59-68.e14.
[13]
Ding W, Zou GL, Zhang W, et al. Interleukin-33:its emerging role in allergic diseases[J]. Molecules, 2018, 23(7):1665.
[14]
Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during inflammatory diseases[J]. Front Immunol, 2017, 8:475.
[15]
Chen WY, Tsai TH, Yang JL, et al. Therapeutic strategies for targeting IL-33/ST2 signalling for the treatment of inflammatory diseases[J]. Cell Physiol Biochem, 2018, 49(1):349-358.
